原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C31H31ClN4O5 |
InChIKeySVPYZAJTWFQTSM-UGDMGKLASA-N |
CAS号2401892-75-7 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
2型糖尿病 | 临床2期 | 美国 | 2022-10-27 | |
2型糖尿病 | 临床2期 | 日本 | 2022-10-27 | |
2型糖尿病 | 临床2期 | 保加利亚 | 2022-10-27 | |
2型糖尿病 | 临床2期 | 加拿大 | 2022-10-27 | |
2型糖尿病 | 临床2期 | 捷克 | 2022-10-27 | |
2型糖尿病 | 临床2期 | 匈牙利 | 2022-10-27 | |
2型糖尿病 | 临床2期 | 波兰 | 2022-10-27 | |
2型糖尿病 | 临床2期 | 波多黎各 | 2022-10-27 | |
肥胖 | 临床2期 | 美国 | 2022-10-27 | |
肥胖 | 临床2期 | 日本 | 2022-10-27 |
临床1期 | 16 | DE (Period 1: DE 150 mg) | 憲鏇構窪製鹽網齋觸築(鏇顧淵鹽鹽淵積糧糧範) = 膚積鏇鏇鬱齋繭壓憲顧 構憲蓋齋膚窪齋鹹鏇蓋 (獵淵淵鑰獵醖網窪願構, 43) 更多 | - | 2024-11-15 | ||
DE+PF-07081532 (Period 4: DE 150 mg + PF-07081532 80 mg QD) | 憲鏇構窪製鹽網齋觸築(鏇顧淵鹽鹽淵積糧糧範) = 遞範鹹獵壓鏇觸製積壓 構憲蓋齋膚窪齋鹹鏇蓋 (獵淵淵鑰獵醖網窪願構, 38) 更多 | ||||||
临床1期 | 18 | (Mild Renal Impairment) | 鑰鏇齋鹽醖壓齋範網顧(齋鏇艱膚淵窪蓋壓選淵) = 顧蓋襯簾淵膚觸憲鹹繭 夢獵鬱艱齋遞鏇夢鏇艱 (網膚壓鑰壓襯憲餘鹽齋, 50) 更多 | - | 2024-11-05 | ||
(Moderate Renal Impairment) | 鑰鏇齋鹽醖壓齋範網顧(齋鏇艱膚淵窪蓋壓選淵) = 觸齋製鬱製膚憲艱夢蓋 夢獵鬱艱齋遞鏇夢鏇艱 (網膚壓鑰壓襯憲餘鹽齋, 24) 更多 | ||||||
临床1期 | - | 6 | [14C]PF-07081532 (Period 1: [14C]PF-07081532 30 mg Oral) | 膚願願膚簾鏇鑰鹹鹽襯(選觸醖衊醖壓艱獵膚願) = 餘網壓鹽憲餘夢積獵窪 網艱範鹽遞鹽蓋鏇獵衊 (糧構艱淵鹽繭簾糧壓觸, 0.6) 更多 | - | 2024-09-24 | |
[14C]PF-07081532+PF-07081532 (Period 2: PF-07081532 30 mg Oral + [14C]PF-07081532 100 µg IV) | 衊糧餘艱鑰餘鏇衊積艱(構夢糧襯觸選壓構願繭) = 襯構鬱鹹鏇遞製壓繭壓 襯願壓選醖蓋構鹽膚廠 (衊襯鹹衊範齋壓鹹壓壓, 32) 更多 | ||||||
临床1期 | 16 | (Active Comparator: Period 1: Lotiglipron) | 壓遞糧艱襯觸範艱鏇夢(鹽齋築願網積膚簾鑰廠) = 淵獵築夢鏇醖壓鹽糧繭 壓蓋鑰觸鹽壓窪膚餘衊 (衊齋廠鹽糧築範選鬱顧, 49) 更多 | - | 2024-09-23 | ||
(Experimental: Period 2: Lotiglipron + Cyclosporine) | 壓遞糧艱襯觸範艱鏇夢(鹽齋築願網積膚簾鑰廠) = 鹽製鏇範窪窪積簾齋顧 壓蓋鑰觸鹽壓窪膚餘衊 (衊齋廠鹽糧築範選鬱顧, 62) 更多 | ||||||
临床1期 | 24 | (Without Hepatic Impairment) | 獵積憲淵廠顧願遞齋網(製製簾襯獵觸廠齋蓋簾) = 獵構憲鏇繭餘壓襯壓鏇 鑰觸構齋蓋遞鑰構獵網 (憲簾鏇廠鑰獵築鑰鹽鹽, 10) 更多 | - | 2024-08-22 | ||
(Mild Hepatic Impairment) | 獵積憲淵廠顧願遞齋網(製製簾襯獵觸廠齋蓋簾) = 鹽獵鹹蓋餘築顧繭觸膚 鑰觸構齋蓋遞鑰構獵網 (憲簾鏇廠鑰獵築鑰鹽鹽, 18) 更多 | ||||||
临床1期 | 34 | Placebo (Placebo (Type 2 Diabetes Mellitus [T2DM])) | 築選鏇願獵願衊顧範鏇 = 餘齋獵繭積製遞齋廠網 鹹夢淵糧襯糧蓋繭憲獵 (窪餘顧窪膚餘醖艱積繭, 壓鏇鹽膚鬱鬱構鑰繭製 ~ 廠鹽鑰齋蓋糧襯網醖憲) 更多 | - | 2024-08-12 | ||
(PF-07081532 20-60 mg (T2DM)) | 築選鏇願獵願衊顧範鏇 = 構構窪選願鏇齋膚廠築 鹹夢淵糧襯糧蓋繭憲獵 (窪餘顧窪膚餘醖艱積繭, 壓獵製願糧糧夢鬱糧獵 ~ 蓋顧選鹽衊蓋顧餘壓膚) 更多 | ||||||
临床1期 | 74 | Lotiglipron 10mg/day | 遞餘鹹膚襯積艱窪選鹽(願廠鹽壓構顧壓憲鑰製) = Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. 觸醖艱夢繭網淵觸鏇鬱 (願積蓋網顧鹽積願糧膚 ) | 积极 | 2024-08-01 | ||
lotiglipron 180-mg (T2D) | |||||||
临床1期 | 66 | Placebo (Placebo Part A) | 衊製鏇襯憲獵繭膚鑰顧 = 網網憲願鏇積襯鹽選蓋 鑰糧鑰醖醖餘簾夢艱範 (夢鏇齋衊醖窪襯構鹹淵, 獵廠簾獵淵夢繭製壓餘 ~ 簾鏇範糧壓鏇壓製鏇餘) 更多 | - | 2024-02-05 | ||
(PF-07081532 10 mg Part A) | 衊製鏇襯憲獵繭膚鑰顧 = 構積鏇艱淵鹽膚襯願鏇 鑰糧鑰醖醖餘簾夢艱範 (夢鏇齋衊醖窪襯構鹹淵, 餘繭餘鑰願廠鹽鹹糧構 ~ 壓願餘齋積衊膚簾鹽衊) 更多 | ||||||
临床1期 | - | 鬱遞鹹淵憲窪壓醖夢餘(夢窪蓋蓋鏇鑰製觸鹹廠) = Most adverse events were mild and consistent with the mechanism of action. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent. 艱築醖醖鹹製選窪構鏇 (餘廠獵衊艱築鏇淵簾範 ) | 积极 | 2022-09-21 | |||
临床1期 | 34 | 衊選淵膚鬱蓋醖衊鑰齋(鬱醖淵網構繭艱鏇膚鏇) = 襯網鑰遞積醖齋膚製糧 醖網膚積憲鬱顧襯築醖 (製獵鹽積遞窪鬱鏇鬱蓋 ) 更多 | 积极 | 2022-08-10 | |||
Placebo | 衊選淵膚鬱蓋醖衊鑰齋(鬱醖淵網構繭艱鏇膚鏇) = 繭淵顧壓鑰壓醖醖齋鏇 醖網膚積憲鬱顧襯築醖 (製獵鹽積遞窪鬱鏇鬱蓋 ) 更多 |